2 Top Telehealth Stocks To Invest In Today
We delve into two alternative telehealth stocks to the dominant player Teladoc, sitting below their highs that could be a good buy today.
Nov. 10, 2021

The U.S. healthcare industry is ripe for disruption, with roughly one-fifth of the national GDP spent on healthcare. These two companies are leveraging telehealth to grow and disrupt and are a top investment today.

Hims & Hers Health: Bull v.s. Bear arguments: 

Hims & Hers Health (NYSE: HIMS) is a multi-specialty telehealth platform that provides over-the-counter prescription drugs and personal care products online. This company's stock price is sitting below the $10 per share that it went public at in its $1.6 billion SPAC merger in 2021.

Hims & Hers has a mission to "eliminate stigmas and make it easier for people to access care and treatment", particularly for conditions that people feel embarrassed about, such as sexual health, hair loss, among others. Its telehealth platform has been key to growth, allowing access to healthcare through licensed professionals and facilitating telehealth visits in all 50 states. It is primarily targeting Millenials and currently has 453,000 subscribers and a net promoter score of 65.

It continues to impress financially with 69% revenue growth year-over-year in Q2 2021, reaching $60.7 million, with 78% gross margins and no debt. The majority of this revenue is subscription-based, and management also raised fiscal 2021 guidance. Beyond digital, it was recently announced that Walgreens is also carrying its products in 7,000 stores. There is a colossal opportunity with management estimating its market opportunity to be in the region of $65 billion.

Despite its rapid growth, its net loss also surged to $9.2 million, and competition is rife from all angles. Hims & Hers has also reported lower guidance since going public, which may cause concern. 

Doximity: Bull v.s. Bear arguments: 

Doximity (NYSE: DOCS) is a digital platform that allows doctors to connect and collaborate with colleagues, offer telehealth visits, coordinate patient care, and more. The company doubled after going public in 2021, but its stock has since retreated. 

Doximity has 1.8 million medical professionals and is the "leading digital platform" with 80% of U.S. medical professionals on it. This creates a network effect and is a competitive advantage with its users also rating the platform highly on the iOS App Store with 4.8 stars out of 5. 

The company primarily makes money by selling subscription-based advertising to pharmaceutical companies. It reported revenue growth of 76% YoY to $45.1 million and a 173% net revenue retention rate in fiscal Q2 2021. It is also profitable, with a net income of $36.1 million.

It estimates that its total addressable market is $18.5 billion and growing. One area where it has experienced rapid growth is telehealth which was only launched in 2020, where it facilitated 63 million visits in fiscal 2021 and now has 330,000 physicians. This should enable it to grow its ecosystem and engage its users. 

The large number of medical professionals on its platform means that the company will continue to upsell and attract advertisers to drive revenue growth. The company has also hinted at expanding into other areas, presenting both an opportunity and execution risk.

To find other worthy investments, check out MyWallSt's shortlist of market-beating stocks. Click here to get free access.

Top Ten Stocks To Buy Now
Commit to your future wealth today and join 1000s of subscribers receiving:
  • New stock picked every week out of 60,000 worldwide
  • Ten Foundational stocks to hold until 2034
  • A library of 60 stocks with analysis
  • 10 year Track record of performance
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

The Home of Successful Investing.

© 2024 MyWallSt Ltd. All rights reserved.







This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.